Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have been diagnosed with Type 2 Diabetes on diet and exercise and/or a stable dose of metformin
Have a stable body weight for the 3 months prior to randomization
Have a body mass index (BMI) ≥23 kilogram/square meter (kg/m²)
Males must agree to use highly effective methods of contraception
Women not of childbearing potential (WNOCBP) may participate in this trial
Note: Hormone replacement therapy in post-menopausal women is allowed but women must be on stable therapy for 3 months prior to day 1.
You may not be if
Have Type 1 diabetes mellitus (T1DM) or history of ketoacidosis or hyperosmolar coma
Have a history of diabetic retinopathy, diabetic maculopathy, or severe non-proliferative diabetic retinopathy that requires immediate treatment intervention
Have had more than 1 episode of severe hypoglycemia and aware of hypoglycemic symptoms
Have acute or chronic pancreatitis
Have obesity induced other endocrine disorders (Cushing's syndrome or Prader - Willi syndrome)
Have gastric emptying abnormality or chronically take medications impacting GI motility
Have poorly controlled hypertension
Have the following heart conditions within the last 6 months: myocardial infarction (MI), unstable angina, coronary artery bypass graft, percutaneous coronary intervention (diagnostic angiograms are permitted), transient ischemic attack (TIA), cerebrovascular accident (stroke)or decompensated congestive heart failure, or IV heart failure
Have any symptoms of other liver diseases besides nonalcoholic fatty liver disease (NAFLD)
Have HIV, or Hepatitis B or Hepatitis C
Clareo Health | A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus
